Francis deSouza, Illumina CEO (Photo by Kevin Dietsch/Getty Images)

Il­lu­mi­na pre­vails over FTC's chal­lenge of $8B Grail buy­out

An ad­min­is­tra­tive judge ruled Il­lu­mi­na’s $8 bil­lion ac­qui­si­tion of can­cer-test­ing com­pa­ny Grail didn’t vi­o­late an­titrust law, Il­lu­mi­na said on Thurs­day.

A Fed­er­al Trade Com­mis­sion law­suit threat­ened to un­wind Il­lu­mi­na’s ac­qui­si­tion of Grail, a blood test­ing com­pa­ny that screens for can­cers at an ear­ly stage.

“As we’ve stat­ed from the out­set, this trans­ac­tion is pro­com­pet­i­tive, will ad­vance in­no­va­tion, low­er health­care costs and save lives,” Il­lu­mi­na gen­er­al coun­sel Charles Dadswell said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.